Cambridge Investment Research Advisors Inc. Trims Position in Humana Inc. (NYSE:HUM)

Cambridge Investment Research Advisors Inc. reduced its position in shares of Humana Inc. (NYSE:HUM) by 17.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,495 shares of the insurance provider’s stock after selling 1,172 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Humana were worth $2,668,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Earnest Partners LLC raised its holdings in Humana by 2.1% during the fourth quarter. Earnest Partners LLC now owns 62,846 shares of the insurance provider’s stock worth $32,189,000 after purchasing an additional 1,313 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in Humana by 0.8% during the fourth quarter. Thrivent Financial for Lutherans now owns 7,465 shares of the insurance provider’s stock worth $3,824,000 after purchasing an additional 58 shares in the last quarter. Schechter Investment Advisors LLC raised its holdings in Humana by 40.5% during the first quarter. Schechter Investment Advisors LLC now owns 1,092 shares of the insurance provider’s stock worth $530,000 after purchasing an additional 315 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Humana by 13.3% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,638 shares of the insurance provider’s stock worth $25,081,000 after purchasing an additional 6,062 shares in the last quarter. Finally, Patton Fund Management Inc. purchased a new position in Humana during the fourth quarter worth about $2,693,000. 91.86% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

NYSE:HUM opened at $460.61 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.58. The company has a market cap of $57.07 billion, a P/E ratio of 17.19, a P/E/G ratio of 1.24 and a beta of 0.66. Humana Inc. has a fifty-two week low of $423.29 and a fifty-two week high of $571.30. The firm’s 50 day moving average is $463.26 and its two-hundred day moving average is $489.36.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $8.94 earnings per share for the quarter, topping analysts’ consensus estimates of $8.88 by $0.06. The company had revenue of $26.75 billion for the quarter, compared to the consensus estimate of $25.83 billion. Humana had a net margin of 3.42% and a return on equity of 20.70%. Humana’s revenue was up 13.0% on a year-over-year basis. During the same quarter last year, the firm posted $8.67 earnings per share. Analysts expect that Humana Inc. will post 28.25 EPS for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 29th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s dividend payout ratio is currently 13.21%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on HUM shares. Morgan Stanley lowered their target price on shares of Humana from $637.00 to $624.00 and set an “overweight” rating on the stock in a research report on Wednesday. Truist Financial upped their target price on shares of Humana from $530.00 to $550.00 and gave the stock a “hold” rating in a research report on Thursday, August 3rd. Royal Bank of Canada lowered their target price on shares of Humana from $637.00 to $594.00 and set an “outperform” rating on the stock in a research report on Thursday, August 3rd. StockNews.com initiated coverage on shares of Humana in a research report on Thursday, August 17th. They set a “buy” rating on the stock. Finally, Barclays lowered their price target on shares of Humana from $620.00 to $585.00 in a research report on Monday, June 19th. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $592.30.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.